Eli Lilly gets FDA green light for Emgality for migraine

Press enter to search
Close search
Open Menu

Eli Lilly gets FDA green light for Emgality for migraine

By Sandra Levy - 09/28/2018
Eli Lilly has received the Food and Drug Administration’s blessing for Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.

Migraine is a disabling, neurologic disease that affects more than 30 million American adults, according to the company.

"Despite the devastating impact of migraine, only about 10% of people living with the disease are currently taking a preventive treatment," Lilly bio-medicines president Christi Shaw said, in a statement. "For more than two decades, Lilly has recognized this unmet need, and we have worked tirelessly to develop a new option specifically designed for the prevention of migraine. With this approval, we are thrilled to offer a preventive treatment option to adults living with this disease."

RELATED TOPICS